MedTrace Logo

A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)

NCT00652769 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2017-11-01

No results posted yet for this study

Summary

In the UK, staging of lung cancer is time consuming (taking on average more than 3 weeks), costly and inaccurate in up to 20% of cases. The investigators wish to determine whether using the newer techniques of endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) improves lung cancer staging. The investigators' hypothesis is that EUS (endoscopic ultrasound) or EBUS (endobronchial ultrasound guided transbronchial needle aspirate) as a first test after CT scan in the diagnosis and staging of lung cancer will result in a reduction in the time from first outpatient appointment to treatment decision, a reduction in the total number of scans and investigative operations, fewer outpatient attendances and a reduction in healthcare costs.

Conditions

  • Bronchogenic Carcinoma

Interventions

PROCEDURE

Endobronchial or Endoscopic Ultrasound

Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.

PROCEDURE

Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy

Investigations will be determined by the multi-disciplinary team responsible for the patient

Sponsors & Collaborators

  • North Middlesex University Hospital

    collaborator OTHER

  • Barnet and Chase Farm Hospitals NHS Trust

    collaborator OTHER

  • The Whittington Hospital NHS Trust

    collaborator OTHER_GOV

  • University College London Hospitals

    lead OTHER

Principal Investigators

  • Stephen Spiro, MD · Univeristy College London NHS Trust

  • Sam Janes, MD PhD · University College, London

  • Neal Navani, MD · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-09-30
Completion
2012-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652769 on ClinicalTrials.gov